2025-07-13 - Analysis Report
Okay, here's an analysis of Merck & Co Inc (MRK) based on the provided data.

**Report on Merck & Co Inc (MRK)**

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** MRK
*   **Company Overview:** Merck & Co Inc is a global pharmaceutical company that develops and markets a wide range of innovative medicines and vaccines.

*   **MRK Cumulative Return:** -0.0401889217763518 (-4.02%)
*   **VOO Cumulative Return:** 95.46151685210242 (95.46%)
*   **Relative Divergence:** Current: -95.4, Relative: 3.3

**Analysis:** MRK has significantly underperformed the S&P 500 (VOO) over the period. The relative divergence of 3.3 indicates that MRK's underperformance is near the lower end of its historical range compared to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha   | Beta   | Cap(B) |
|------------|--------|-------|---------|--------|--------|
| 2015-2017  | 5.0%   | 58.2% | -24.0%  | -0.0   | 134.8  |
| 2016-2018  | 43.0%  | 66.4% | 25.0%   | -0.1   | 183.1  |
| 2017-2019  | 40.0%  | 66.4% | 11.0%   | 0.3    | 217.9  |
| 2018-2020  | 20.0%  | 66.4% | 0.0%    | 0.3    | 196.0  |
| 2019-2021  | -1.0%  | 65.6% | -50.0%  | 0.3    | 192.4  |
| 2020-2022  | 13.0%  | 69.5% | 11.0%   | 0.3    | 278.6  |
| 2021-2023  | 31.0%  | 69.5% | 13.0%   | 0.3    | 273.8  |
| 2022-2024  | -7.0%  | 69.5% | -33.0%  | 0.2    | 249.8  |
| 2023-2025  | -52.0% | 61.4% | -99.0%  | 0.5    | 209.3  |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate shows fluctuating performance across different periods.  The recent period (2023-2025) exhibits a significant decline.
*   **MDD:**  Maximum Drawdown is consistently high, indicating significant potential for losses.
*   **Alpha:** Alpha is predominantly negative, indicating underperformance relative to the benchmark. The most recent period shows a very large negative alpha.
*   **Beta:** Beta is relatively low, suggesting MRK is less sensitive to market movements. However, the Beta has been trending upwards.
*   **Cap(B):** The market capitalization has varied over time, showing overall growth but a recent decline.

**2. Recent Price Action**

*   **Current Price:** 83.36
*   **Previous Close:** 84.02
*   **Change:** -0.79 (Decrease)
*   **5-Day Moving Average:** 82.672
*   **20-Day Moving Average:** 80.8174
*   **60-Day Moving Average:** 79.4456

**Analysis:** The stock price has decreased slightly in the most recent trading session.  The price is above all three moving averages, suggesting a short-term and intermediate-term uptrend. However, the recent decline suggests a potential loss of momentum.

**3. Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.3294 (Low Risk)
*   **RSI:** 70.3263940772608 (Overbought)
*   **PPO:** 0.469
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.33)
*   **Recent (20-day) Relative Divergence Change:** 1.4 (+) (Short-term Increase)
*   **Expected Return:** -315.5% (vs. S&P 500, long-term)

**Analysis:**

*   The MRI indicates low market risk.
*   The RSI is in overbought territory, suggesting the stock may be due for a pullback.
*   The Hybrid Signal is suggesting to buy with caution due to MRI.
*   The positive change in relative divergence indicates a short-term increase in performance relative to the benchmark, but the long-term expected return is extremely negative.
*   The recent negative change in price (price': 83.36, 'previousClose': 84.02, 'change': -0.79) does show a slight price decrease. This, coupled with the overbought RSI, signals a potential short-term risk.

**4. Recent News & Significant Events**

*   **[2025-07-10]:** Major business developments, regulatory changes, or market events.
*   **[2025-07-12]:** Analyst discussions on recent performance and outlook.
*   **[2025-07-13]:** Stock volatility influenced by recent news, earnings, or executive actions.
*   **[2025-07-11]:** Market experts highlighting both risks and opportunities.

**Analysis:** The news suggests recent volatility and the need for caution. Investors should pay close attention to upcoming news and company announcements.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue      |
|------------|------|--------------|
| 2025-05-02 | 2.01 | 15.53 B$     |
| 2024-11-06 | 1.25 | 16.66 B$     |
| 2024-08-05 | 2.15 | 16.11 B$     |
| 2024-05-03 | 1.88 | 15.78 B$     |
| 2025-05-02 | 1.88 | 15.78 B$     |

**Analysis:** EPS and revenue figures have fluctuated.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-03-31 | $15.53B   | 77.98%        |
| 2024-12-31 | $15.62B   | 75.50%        |
| 2024-09-30 | $16.66B   | 75.51%        |
| 2024-06-30 | $16.11B   | 76.76%        |
| 2024-03-31 | $15.78B   | 77.56%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE     |
|------------|-----------|---------|
| 2025-03-31 | $48.34B   | 10.51%  |
| 2024-12-31 | $46.31B   | 8.08%   |
| 2024-09-30 | $44.50B   | 7.09%   |
| 2024-06-30 | $43.58B   | 12.52%  |
| 2024-03-31 | $40.36B   | 11.80%  |

**Analysis:**

*   **Revenue:** Revenue has been relatively stable.
*   **Profit Margin:** Profit margins are strong and consistent.
*   **Equity:** Equity has shown consistent growth.
*   **ROE:** ROE has fluctuated, indicating variability in the company's ability to generate profit from equity.

**7. Overall Analysis**

Merck & Co Inc (MRK) has significantly underperformed the S&P 500, with a large negative expected return. While recent price action suggests a short-term uptrend, the RSI indicates overbought conditions, and the overall technical picture is mixed.  Recent news highlights volatility and uncertainty.  The company has strong profit margins and growing equity, but ROE has fluctuated.  The negative Alpha and recent large decline in CAGR and Alpha are concerning.

**Recommendation:**

Based on this analysis, a cautious approach is warranted. While the MRI indicates low market risk, the significantly negative expected return relative to the S&P 500, the high volatility and overbought RSI suggests potential downside risk. Further investigation into the reasons for the underperformance, the recent news events, and the extremely negative expected return is necessary before making any investment decisions.
